Investors

Circulating tumor cells (CTCs) are a clinically validated predictor of treatment response and survival across multiple solid tumors and are increasingly used as diagnostic and prognostic tools. However, current clinical identification of CTCs is limited to diagnostic rather than therapeutics. 

​

 

OnConquer Medical introduces a first-in-class therapeutic approach by physically removing CTCs from circulation in real-time. By targeting the direct precursors of metastasis, CTCapture® addresses one of the root cause of metastatic disease, creating a new interventional opportunity complementary to existing oncology therapies.